hichemben
Oct 3, 8:38 AM
$WVE Still can't understand today price action / current valuation with
$502M in cash compared to beam & vikings valuations🤯 Only 6-8 weeks left for both readouts to find out if we hit
$8 or
$15 (
$3B)🚀
1- Beam302 Vs Wve006: Both programs share an identical FDA 1-year Accelerated Approval biomarker surrogate pathway. However, Beam requires complex systemic lipid nanoparticle (LNP) intravenous infusions, whereas WVE-006 is administered as a convenient subcutaneous GalNAc injection. Despite having an easier-to-administer modality and an equivalent regulatory route, Wave's EV is heavily discounted relative to Beam.
2- Viking’s valuation is driven by metabolic/obesity indications (VK2735). Wave’s clinical obesity asset, WVE-007 (INHBE GalNAc-siRNA), targets fat reduction while preserving lean muscle mass, yet the market currently attributes near-zero value to WVE-007 within Wave's sub-
$750M market cap.
1 replies
